ClinicalTrials.Veeva

Menu
S

Southeastern Research Center | Winston-Salem, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BI 1015550
Tiotropium
Olodaterol
Dupilumab
Astegolimab
BMS-986278
Treprostinil
BLU-5937
INS018_055
SUN-101

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

27 of 52 total trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

HZNP-HZN-825-303 (HARBOR) comprises of 2 parts. Part 1 (Core Phase) is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial...

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: HZN-825
Drug: Placebo

ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this...

Enrolling
Bronchiectasis
Drug: Placebo
Drug: Itepekimab (SAR440340)

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmo...

Enrolling
Systemic Sclerosis With Lung Involvement
Idiopathic Pulmonary Fibrosis
Drug: Vixarelimab
Drug: Placebo

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus pla...

Enrolling
Progressive Pulmonary Fibrosis
Drug: AP01
Other: Placebo
Locations recently updated

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo

The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as...

Enrolling
Alpha1-Antitrypsin Deficiency
Biological: Alpha-1 15%
Biological: Liquid Alpha1-Proteinase Inhibitor (Human)

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Astegolimab
Locations recently updated

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling
Progressive Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BI 1015550

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: BI 1015550
Drug: Placebo

To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: Leramistat

This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment f...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: Placebo matching BI 1819479
Drug: BI 1819479

Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can partici...

Enrolling
Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Drug: BI 1839100
Drug: Placebo
Locations recently updated

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and phar...

Enrolling
Idiopathic Pulmonary Fibrosis (IPF)
Drug: Placebo
Drug: Buloxibutid

This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: Tazarotene (GRI-0621)
Locations recently updated

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.

Invitation-only
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Device: Treprostinil Ultrasonic Nebulizer
Drug: Inhaled Treprostinil

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults wit...

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Deupirfenidone
Drug: Placebo

Trial sponsors

Boehringer Ingelheim logo
Sanofi logo
Baxalta logo
B
B
Bristol-Myers Squibb (BMS) logo
Genentech logo
I
P
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems